Teva Pharmaceutical Industries, a top pharma establishments has suspended testing of its generic version of Rituxan, a $7-billion a year drug, at the third stage of clinical trials.
The top pharma giant has suspended third-phase testing of its generic version of the $7 billion a year drug Rituxan, used in the treatment of cancer and rheumatoid arthritis.
For further deal information visit Current Agreements (subscription required)
Read: more on big pharma deals in pharma, biotech, life science partnering deal news, insights and glossary
Read: Big pharma deal news – latest deal news for top 50 pharma / big pharma companies
Report: Partnering Deals and Alliances with Teva
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now
Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now
Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more